Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) subsidiary Aitmei intends to increase capital and expand shares.

Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) announced that its subsidiary, Eteam (Suzhou) Medical Technology Co., Ltd. (referred to as "Eteam"), plans to increase its capital and expand its shareholding. This includes: Suzhou Hongbo Second Phase Investment Partnership Enterprise (Limited Partnership) intends to invest 50 million yuan, Suzhou Dongwu Industrial M&A Guidance Fund Partnership Enterprise (Limited Partnership) intends to invest 50 million yuan, and Suzhou Longtaohezhi Enterprise Management Partnership Enterprise (Limited Partnership) intends to invest 3 million yuan. The company has waived its preemptive rights for this capital increase. Prior to this round of investment, Brightgene Bio-Medical Technology Co., Ltd. implemented debt-to-equity conversion for Eteam. Taking into account the debt-to-equity conversion arrangement and the completion of this round of investment, the company's equity stake in Eteam will change from 57.3600% to 55.0044%. Eteam will remain a subsidiary of the company and will not affect the consolidated financial statements of the company.